Aytu BioPharma to Present at Upcoming October 2025 Conferences

Rhea-AI Summary

Aytu BioPharma (NASDAQ:AYTU) announced that management will participate in two investor conferences in October 2025.

Events: Maxim Growth Summit on October 22, 2025 in New York City, and Planet MicroCap Showcase: TORONTO 2025 on October 22–23, 2025 in Toronto. The Planet MicroCap presentation is scheduled for 2:30 p.m. ET and will be available via webcast.

Investor access: Investors may schedule one-on-one meetings by contacting their Maxim sales representative or Robert Blum of Lytham Partners at aytu@lythampartners.com. Registration is required to attend the Planet MicroCap Showcase and the webcast link is provided for remote viewing.

DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:

2025 Maxim Growth Summit

Date: October 22, 2025
Location: New York City

Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com to schedule one-on-one meetings with Aytu's management.

Planet MicroCap Showcase: TORONTO 2025

Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja

If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at aytu@lythampartners.com to assist in coordination.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA^™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT^® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal^® ER (carbinoxamine maleate), Poly-Vi-Flor^® and Tri-Vi-Flor^®. To learn more, please visit aytubio.com.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Aytu BioPharma (AYTU) present at the Planet MicroCap Showcase: TORONTO 2025?

Aytu will present on October 22–23, 2025; the company’s presentation is at 2:30 p.m. ET on the scheduled date.

How can investors schedule one-on-one meetings with Aytu (AYTU) management at the October 2025 conferences?

Investors should contact their Maxim sales representative or email Robert Blum at aytu@lythampartners.com to arrange meetings.

Is there a webcast to watch Aytu BioPharma (AYTU) presentation remotely for the Planet MicroCap Showcase?

Yes, the Planet MicroCap presentation will be available via webcast at the provided event link.

What date is Aytu attending the Maxim Growth Summit in 2025?

Aytu’s management will participate in the Maxim Growth Summit on October 22, 2025 in New York City.

Where can I register to attend the Planet MicroCap Showcase: TORONTO 2025 with Aytu (AYTU)?

Registration is required to attend the Planet MicroCap Showcase; interested investors should use the event registration link or contact Robert Blum at aytu@lythampartners.com.